Follow up immunogenicity of a mixed vaccination schedule with one dose of nonavalent and one dose of bivalent HPV vaccines 36 months post-vaccination among boys and girls.
VaccineSep 3, 2026 (epub)
Iulia Gabriela Ionescu, Manale Ouakki, Olivier Breton et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial evaluated the long-term immunogenicity of mixed HPV vaccination schedules (one dose of nonavalent and one dose of bivalent) in boys and girls aged 9-10 years, 36 months post-vaccination. Results showed that 100% of participants had detectable antibodies for HPV16 and HPV18, with significantly higher geometric mean concentrations (GMCs) for these types in the mixed schedule compared to a homologous two-dose nonavalent schedule.
Key findings
- 100% of participants had detectable antibodies for HPV16 and HPV18 at 36 months.
- GMCs for HPV16 were significantly higher in mixed schedules: 184.6 vs 97.7.
- GMCs for HPV18 were also higher in mixed schedules: 70.4 vs 40.3.
- No substantial differences in immune response were observed between boys and girls.
Why it matters
Understanding the long-term immunogenicity of mixed HPV vaccination schedules is crucial for informing vaccination strategies and public health policies aimed at preventing HPV-related diseases.